Stay in the know
We’ll send you the latest insights and briefings tailored to your needs
Subscribe now
Herbert Smith Freehills Kramer (HSF Kramer) is pleased to be advising CSL on its recently announced proposed demerger of its Seqirus business (Seqirus) as a standalone ASX-listed entity by the end of Financial Year 2026.
Seqirus is one of the world’s largest influenza vaccine providers, dedicated to advancing public health through innovative vaccine solutions and pandemic preparedness.
The HSF Kramer team is led by partners Priscilla Bryans, Baden Furphy, Alexander Mackinnon, and Michael Ziegelaar, with partner Ryan Leslie advising on the tax aspects of the transaction.
Key contacts
Priscilla Bryans
Partner, Melbourne
Baden Furphy
Partner, Melbourne
Alexander Mackinnon
Partner, Melbourne
Michael Ziegelaar
Partner, Melbourne
Ryan Leslie
Partner, Melbourne
Media contact
For further information on this news article, please contact:
Gina Baldassarre
External Communications Manager
Sydney
More news
5 6월 2026
Herbert Smith Freehills Kramer assists Ampol to secure ACCC clearance for its A$1.1 billion acquisition of EG Australia – the first Phase II clearance under Australia’s new merger regime
HSF Kramer has advised Ampol Limited on securing ACCC clearance for its proposed $1.1 billion acquisition of EG Australia. The ACCC approved Ampol’s …
5 6월 2026
Herbert Smith Freehills Kramer leads at London International Disputes Week
Herbert Smith Freehills Kramer has played a leading role in London International Disputes Week (LIDW) 2026, reinforcing the firm's position at the heart …
4 6월 2026
Herbert Smith Freehills Kramer recognized for excellence in Chambers USA 2026
Chambers USA has recognized Herbert Smith Freehills Kramer across 25 practice categories and ranked 50 individuals as part of its 2026 guide. This …